Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24

Sun Pharmaceutical Industries Ltd. announced that its leading biologic drug, Ilumya (tildrakizumab-asmn), achieved the primary endpoint in both INSPIRE-1 and INSPIRE-2 Phase 3 clinical studies for active psoriatic arthritis (PsA). At Week 24, patients receiving Ilumya experienced statistically significant improvements over placebo, as measured by the ACR20 response—indicating at least a 20% reduction in tender and swollen joints and other disease indicators.

Ilumya, a selective IL-23 inhibitor, blocks key inflammatory pathways in autoimmune conditions. Already approved for moderate-to-severe plaque psoriasis, the drug generated $681 million (₹5,750 crore) in FY25, accounting for 56% of Sun Pharma’s specialty drug revenue.

Sun Pharma’s global specialty chief, Marek Honczarenko, highlighted that these results reinforce Ilumya’s potential as a new therapeutic option for PsA. Full trial data will be shared at upcoming medical conferences.

Competition is intensifying in the psoriatic arthritis market, with Bristol Myers Squibb’s oral TYK2 inhibitor Sotyktu also meeting ACR20 response in late-stage trials and achieving $246 million in 2024 sales. As both injectable and oral therapies advance, patients could soon benefit from more effective and diverse treatment choices.